"Patient Advocacy Spurs Eli Lilly to Address Zepbound Shortage for Obesity Treatment"
Originally Published 1 year ago — by Bloomberg
Patients are struggling to access the weight-loss shot Zepbound due to a shortage of the pre-filled pens used to administer the drug, prompting calls for Eli Lilly & Co. to release more supply. The company's CEO cited the complexity of production systems as a factor contributing to the shortage.